EMERGENT BIOSOLUTIONS INC (EBS)
US29089Q1058 - Common Stock
ChartMill assigns a Buy % Consensus number of 47% to EBS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.1. This target is 133.94% above the current price.
EBS was analyzed by 9 analysts. The buy percentage consensus is at 47. So analysts seem to be rather neutral about EBS.
In the previous month the buy percentage consensus was at a similar level.
EBS was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-11 | Benchmark | Reiterate | Buy -> Buy |
| 2024-03-07 | Benchmark | Upgrade | Hold -> Buy |
| 2023-11-20 | JP Morgan | Reiterate | Underweight |
| 2023-08-29 | Benchmark | Downgrade | Buy -> Hold |
| 2023-05-31 | Benchmark | Reiterate | Buy -> Buy |
| 2023-05-19 | Benchmark | Reiterate | Buy -> Buy |
| 2023-04-10 | Benchmark | Upgrade | Hold -> Buy |
| 2023-03-17 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2022-11-10 | Benchmark | Downgrade | Buy -> Hold |
| 2022-11-09 | Chardan Capital | Maintains | Buy |
| 2022-09-12 | Cowen & Co. | Maintains | Market Perform |
| 2022-05-04 | Wells Fargo | Maintains | Equal-Weight |
| 2022-04-29 | Chardan Capital | Maintains | Buy |
| 2022-03-10 | Wells Fargo | Maintains | Equal-Weight |
| 2021-11-10 | Chardan Capital | Maintains | Buy |
| 2021-11-08 | Benchmark | Downgrade | Buy -> Hold |
| 2021-05-05 | Argus Research | Downgrade | Buy -> Hold |
| 2021-04-30 | Chardan Capital | Maintains | Buy |
| 2021-04-07 | Benchmark | Initiate | Buy |
| 2021-02-24 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2021-02-19 | Chardan Capital | Downgrade | Buy -> Neutral |